LLY Stock Forecast: 2026 Expectations
Names rising to the top of the screen
The strongest names remain easy to scan without losing the valuation context behind the ranking.
| # | Ticker | Company | AI Score | Price | Change | Market Cap | P/E |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly and Company | 96 | $1122.21 | -0.07% | $1.1T | 37.6 |
| 2 | EXEL | Exelixis, Inc. | 98 | $56.20 | -2.14% | $14.4B | 17.5 |
| 3 | KRYS | Krystal Biotech, Inc. | 98 | $345.55 | -0.73% | $10.2B | 41.8 |
| 4 | INCY | Incyte Corporation | 98 | $123.28 | -2.17% | $25.0B | 15.2 |
| 5 | HRMY | Harmony Biosciences Holdings, Inc. | 97 | $41.10 | -1.25% | $2.4B | 13.1 |
| 6 | UTHR | United Therapeutics Corporation | 97 | $503.86 | -0.58% | $21.4B | 16.7 |
| 7 | NHC | National HealthCare Corporation | 97 | $224.92 | -1.02% | $2.2B | — |
| 8 | INSP | Inspire Medical Systems, Inc. | 97 | $73.00 | +7.16% | $2.0B | 14.6 |
| 9 | ETON | Eton Pharmaceuticals, Inc. | 97 | $57.15 | -1.26% | $1.6B | 124.5 |
| 10 | ARGX | argenx SE | 97 | $984.04 | -1.82% | $61.2B | 36.0 |
| 11 | LQDA | Liquidia Corporation | 96 | $67.71 | -0.21% | $6.0B | 43.2 |
| 12 | GRDN | Guardian Pharmacy Services, Inc. | 96 | $43.66 | -0.39% | $2.8B | 41.7 |
Where valuation pressure is clustering
Considerations for LLY in 2026
“MoonshotScore rates a US-listed stock 0 to 100 — higher means stronger numbers. Most carry an older nine-factor score; the rest use five sector-relative pillars, re-ranked daily — common stocks and ADRs only. Funds, ETFs, warrants, units, SPACs, preferreds, and notes carry none. It is built for education and deeper due diligence, not financial advice.”
Questions worth resolving before acting on the screen
What factors could influence Eli Lilly's stock price in 2026?
Key factors include clinical trial results, FDA approvals, competitive pressures, and overall market conditions. Changes in healthcare policy and economic growth may also impact investor sentiment and stock valuation.
How reliable are stock forecasts?
Stock forecasts represent educated guesses about future performance but are not guarantees. They should be viewed as one input among many when making investment decisions, and investors should conduct thorough due diligence.
What other resources are available for researching Eli Lilly?
Investors can consult Eli Lilly's investor relations website, SEC filings, independent research reports, and financial news outlets for additional information. Analyzing multiple sources can provide a more comprehensive understanding of the company.